Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the ...

The efficacy and safety of treatment with cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal-cell carcinoma are unknown. In this phase 3 ...

EXEL's 2025 total revenue guidance is flat at $2.15B-$2.25B, although that doesn't model potential approval of cabozantinib for neuroendocrine tumors. EXEL's STELLAR-303 trial of zanzalintinib in ...

SAN FRANCISCO — Treatment with cabozantinib (Cabometyx, Exelixis) significantly improved outcomes in patients with advanced hepatocellular carcinoma (HCC), leading researchers to suggest that it ...

Cabozantinib plus pembrolizumab could potentially benefit certain patients with advanced urothelial carcinoma who are ineligible for or refuse platinum-based chemotherapy, but more research is ...

A statistically significant and clinically meaningful improvement in PFS was observed with cabozantinib, compared with placebo, in the phase 3 CABINET study. The Food and Drug Administration (FDA ...

– Cabozantinib reduced the risk of disease progression or death by 50 percent compared with placebo in patients with advanced gastrointestinal neuroendocrine tumors – – Supplemental New Drug ...

Exelixis (EXEL) on Wednesday announced that the Food and Drug Administration has approved cabozantinib, or Cabometyx, for the treatment of unresectable, locally advanced or metastatic pancreatic ...

1.1 Cabozantinib is not recommended, within its marketing authorisation, for treating locally advanced or metastatic differentiated thyroid cancer (DTC) that is unsuitable for or refractory to ...